%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Fontbonne, Annick
%A Diouf, I.
%A Baccara-Dinet, M.
%A Eschwege, E.
%A Charles, M. A.
%T Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies : a post-hoc analysis of the BIGPRO1 trial
%D 2009
%L PAR00004369
%G ENG
%J Diabetes and Metabolism
%@ 1262-3636
%K Metformin ; Prediabetes ; Cardiometabolic risk factors ; Clinical trial
%M ISI:000272208900006
%N 5
%P 385-391
%R 10.1016/j.diabet.2009.03.005
%U https://www.documentation.ird.fr/hor/PAR00004369
%> https://www.documentation.ird.fr/intranet/publi/depot/2015-10-26/010065780.pdf
%V 35
%W Horizon (IRD)
%X Aim. - Metformin has recently been considered as a possible pharmacological complement to lifestyle measures for preventing type 2 diabetes in high-risk subjects. However, little is known of its effects on metabolic and cardiovascular risk factors in non-diabetic subjects. Methods. - The BIGPRO1 trial was a 1-year multicentre, randomized, double-blind, controlled clinical trial of metformin versus placebo, carried out in the early 1990s, in 457 upper-body obese non-diabetic subjects with no cardiovascular diseases or contraindications to metformin. We compared the changes (1-year minus baseline) in cardiometabolic risk factors between treatment groups in two subsets of trial subjects: those with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) (n = 101); and those who fulfilled the inclusion criteria of the Diabetes Prevention Program (DPP) (it = 5 1). Comparisons were adjusted for age and gender. Results. - In the IFG/IGT subset, significant differences in 1-year changes were observed for systolic blood pressure, which decreased markedly more in the metformin group than in the placebo group (P < 0.003), and for fasting plasma glucose, and total and LDL cholesterol, which decreased slightly in the metformin group, but increased in the placebo group (P < 0.04). Similar results were observed in the subset with DPP criteria. Also, there were no significant differences in 1-year changes for weight, waist-to-hip ratio, 2-h post-load blood glucose, fasting and 2-h post-load insulin, HDL cholesterol, triglycerides and fibrinolytic markers between the two treatment groups. Conclusion. - In subjects at high risk of developing diabetes, the use of metformin showed beneficial and no untoward effects on cardiometabolic risk factors.
%$ 050